AbbVie, Others Move To End Generic Bystolic Antitrust Claims
AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of...To view the full article, register now.
Already a subscriber? Click here to view full article